YAP1 and sarcoma: The most recent study by Massoth L.R. et al. [108] interrogated public genomic data from 14,680 sarcomas and found 33 patients with KMT2A rearrangements (0.2%), including 16 patients with tumors positive for YAP1::KMT2A fusion.